Abstract

The management of patients with mesothelioma and thymic malignancy requires continuous multidisciplinary expertise at any step of the disease. A dramatic improvement in our knowledge has occurred in the last few years, through the development of databases, translational research programs, and clinical trials. Access to innovative strategies represents a major challenge, as there is a lack of funding for clinical research in rare cancers and their rarity precludes the design of robust clinical trials that could lead to specific approval of drugs. In this context, patient-centered initiatives, such as the establishment of dedicated networks, are warranted. International societies, such as IMIG (International Mesothelioma Interest Group) and ITMIG (International Thymic Malignancy Interest Group) provide infrastructure for global collaboration, and there are many advantages to having strong regional groups working on the same issues. There may be regional differences in risk factors, susceptibility, management and outcomes. The ability to address questions both regionally as well as globally is ideal to develop a full understanding of mesothelioma and thymic malignancies. In Europe, through the integration of national networks with EURACAN, the collaboration with academic societies and international groups, the development of networks in thoracic oncology provides multiplex integration of clinical care and research, ultimately ensuring equal access to high quality care to all patients, with the opportunity of conducting high level clinical and translational research projects.

Original languageEnglish
Pages (from-to)75-80
Number of pages6
JournalEuropean Journal of Surgical Oncology
Volume45
Issue number1
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Thymus Neoplasms
Mesothelioma
Public Opinion
Translational Medical Research
Neoplasms
Clinical Trials
Drug Approval
Quality of Health Care
Therapeutics
Research
Thorax
Databases

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Mesothelioma and thymic tumors : Treatment challenges in (outside) a network setting. / RARECAREnet Working Group.

In: European Journal of Surgical Oncology, Vol. 45, No. 1, 01.01.2019, p. 75-80.

Research output: Contribution to journalArticle

@article{d505821c41384814980b1aee3e084e7a,
title = "Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting",
abstract = "The management of patients with mesothelioma and thymic malignancy requires continuous multidisciplinary expertise at any step of the disease. A dramatic improvement in our knowledge has occurred in the last few years, through the development of databases, translational research programs, and clinical trials. Access to innovative strategies represents a major challenge, as there is a lack of funding for clinical research in rare cancers and their rarity precludes the design of robust clinical trials that could lead to specific approval of drugs. In this context, patient-centered initiatives, such as the establishment of dedicated networks, are warranted. International societies, such as IMIG (International Mesothelioma Interest Group) and ITMIG (International Thymic Malignancy Interest Group) provide infrastructure for global collaboration, and there are many advantages to having strong regional groups working on the same issues. There may be regional differences in risk factors, susceptibility, management and outcomes. The ability to address questions both regionally as well as globally is ideal to develop a full understanding of mesothelioma and thymic malignancies. In Europe, through the integration of national networks with EURACAN, the collaboration with academic societies and international groups, the development of networks in thoracic oncology provides multiplex integration of clinical care and research, ultimately ensuring equal access to high quality care to all patients, with the opportunity of conducting high level clinical and translational research projects.",
author = "{RARECAREnet Working Group} and Martina Imbimbo and Maury, {Jean Michel} and Marina Garassino and Nicolas Girard and Monika Hackl and Eycken, {Elizabeth Van} and Kris Henau and Nadya Dimitrova and Mario Sekerija and Ladislav Dušek and Margit M{\"a}gi and Nea Malila and Maarit Leinonen and Michel Velten and Xavier Troussard and Veronique Bouvier and Guizard, {Anne Val{\'e}rie} and Bouvier, {Anne Marie} and Patrick Arveux and Marc Maynadi{\'e} and Woronoff, {Anne Sophie} and Michel Robaszkiewicz and Isabelle Baldi and Alain Monnereau and Brigitte Tretarre and Marc Colonna and Florence Molini{\'e} and Simona Bara and Claire Schvartz and B{\'e}n{\'e}dicte Lap{\^o}tre-Ledoux and Pascale Grosclaude and Roland Stabenow and Sabine Luttmann and Diego Serraino and {De Angelis}, Roberta and Sandra Mallone and Andrea Tavilla and Daniela Pierannunzio and Silvia Rossi and Mariano Santaquilani and Arnold Knijn and Valerio Gennaro and Mario Fusco and Lucia Mangone and Fabio Falcini and Maria Gentilini and Giovanna Tagliabue and Annalisa Trama and Gemma Gatta and Laura Botta",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ejso.2018.01.078",
language = "English",
volume = "45",
pages = "75--80",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Mesothelioma and thymic tumors

T2 - Treatment challenges in (outside) a network setting

AU - RARECAREnet Working Group

AU - Imbimbo, Martina

AU - Maury, Jean Michel

AU - Garassino, Marina

AU - Girard, Nicolas

AU - Hackl, Monika

AU - Eycken, Elizabeth Van

AU - Henau, Kris

AU - Dimitrova, Nadya

AU - Sekerija, Mario

AU - Dušek, Ladislav

AU - Mägi, Margit

AU - Malila, Nea

AU - Leinonen, Maarit

AU - Velten, Michel

AU - Troussard, Xavier

AU - Bouvier, Veronique

AU - Guizard, Anne Valérie

AU - Bouvier, Anne Marie

AU - Arveux, Patrick

AU - Maynadié, Marc

AU - Woronoff, Anne Sophie

AU - Robaszkiewicz, Michel

AU - Baldi, Isabelle

AU - Monnereau, Alain

AU - Tretarre, Brigitte

AU - Colonna, Marc

AU - Molinié, Florence

AU - Bara, Simona

AU - Schvartz, Claire

AU - Lapôtre-Ledoux, Bénédicte

AU - Grosclaude, Pascale

AU - Stabenow, Roland

AU - Luttmann, Sabine

AU - Serraino, Diego

AU - De Angelis, Roberta

AU - Mallone, Sandra

AU - Tavilla, Andrea

AU - Pierannunzio, Daniela

AU - Rossi, Silvia

AU - Santaquilani, Mariano

AU - Knijn, Arnold

AU - Gennaro, Valerio

AU - Fusco, Mario

AU - Mangone, Lucia

AU - Falcini, Fabio

AU - Gentilini, Maria

AU - Tagliabue, Giovanna

AU - Trama, Annalisa

AU - Gatta, Gemma

AU - Botta, Laura

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The management of patients with mesothelioma and thymic malignancy requires continuous multidisciplinary expertise at any step of the disease. A dramatic improvement in our knowledge has occurred in the last few years, through the development of databases, translational research programs, and clinical trials. Access to innovative strategies represents a major challenge, as there is a lack of funding for clinical research in rare cancers and their rarity precludes the design of robust clinical trials that could lead to specific approval of drugs. In this context, patient-centered initiatives, such as the establishment of dedicated networks, are warranted. International societies, such as IMIG (International Mesothelioma Interest Group) and ITMIG (International Thymic Malignancy Interest Group) provide infrastructure for global collaboration, and there are many advantages to having strong regional groups working on the same issues. There may be regional differences in risk factors, susceptibility, management and outcomes. The ability to address questions both regionally as well as globally is ideal to develop a full understanding of mesothelioma and thymic malignancies. In Europe, through the integration of national networks with EURACAN, the collaboration with academic societies and international groups, the development of networks in thoracic oncology provides multiplex integration of clinical care and research, ultimately ensuring equal access to high quality care to all patients, with the opportunity of conducting high level clinical and translational research projects.

AB - The management of patients with mesothelioma and thymic malignancy requires continuous multidisciplinary expertise at any step of the disease. A dramatic improvement in our knowledge has occurred in the last few years, through the development of databases, translational research programs, and clinical trials. Access to innovative strategies represents a major challenge, as there is a lack of funding for clinical research in rare cancers and their rarity precludes the design of robust clinical trials that could lead to specific approval of drugs. In this context, patient-centered initiatives, such as the establishment of dedicated networks, are warranted. International societies, such as IMIG (International Mesothelioma Interest Group) and ITMIG (International Thymic Malignancy Interest Group) provide infrastructure for global collaboration, and there are many advantages to having strong regional groups working on the same issues. There may be regional differences in risk factors, susceptibility, management and outcomes. The ability to address questions both regionally as well as globally is ideal to develop a full understanding of mesothelioma and thymic malignancies. In Europe, through the integration of national networks with EURACAN, the collaboration with academic societies and international groups, the development of networks in thoracic oncology provides multiplex integration of clinical care and research, ultimately ensuring equal access to high quality care to all patients, with the opportunity of conducting high level clinical and translational research projects.

UR - http://www.scopus.com/inward/record.url?scp=85044792812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044792812&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2018.01.078

DO - 10.1016/j.ejso.2018.01.078

M3 - Article

C2 - 29426781

AN - SCOPUS:85044792812

VL - 45

SP - 75

EP - 80

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 1

ER -